Is Alnylam a Good Biotech Stock to Buy Now?
This biotech could earn its third new drug approval in as many years.
Alnylam Pharmaceuticals
ALNY
ALNY
$152.30
$6.54
4.5%
Price as of August 3, 2020, 4:00 p.m. EDT
View Interactive ALNY Charts
A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.
Interactive Chart
News & Analysis: Alnylam Pharmaceuticals
The Fool has written over 200 articles on Alnylam Pharmaceuticals.
Is Alnylam Pharmaceuticals a Buy?
The stock is up an amazing 2,100% since the company went public, stomping the S&P 500.
Alnylam Pharmaceuticals Inc (ALNY) Q1 2020 Earnings Call Transcript
ALNY earnings call for the period ending March 31, 2020.
Alnylam Pharmaceuticals Lowers 2020 Sales Expectations Due to COVID-19
The impact of the pandemic led the biopharmaceutical company to trim its revenue guidance for polyneuropathy treatment Onpattro.
Vir Biotechnology and Alnylam Pick a Coronavirus Antiviral Candidate to Pursue
The partners will develop VIR-2703, which has the potential to prevent COVID-19, and also to treat it.
2 Top Small-Cap Stocks to Buy Right Now
These development-stage drug companies are well positioned for success, even amid the current market uncertainty.
Alnylam Scores a $2 Billion Investment From Blackstone
The multipart deal will, among other things, give the world's largest alternative investment firm a piece of the profits from the biotech's revolutionary new cholesterol drug.
Better Buy: Alnylam Pharmaceuticals vs. Vir Biotechnology
Will a 14-year head start prove to be an advantage between these biotechs?
Why Alnylam Pharmaceuticals, Intuitive Surgical, and ResMed Stocks Sank Today
Three words: Coronavirus market meltdown.
World Health Organization Says COVID-19 Confirmed Fatality Rate Is 3.4%
The World Health Organization gave context around its confirmed fatality rate for the rapidly-spreading illness.
